Health is Wealth | Unsplash by Hush Naidoo Jade Photography
Health is Wealth | Unsplash by Hush Naidoo Jade Photography
Due to the continued growth of Nebraska Medicine’s Hematology/Oncology Division with 32 physicians and faculty, three new section leader roles have been created.
Each leader will help enhance communication, recruitment, day-to-day operational efficiencies and educational needs.
Section leaders announced within the division are:
- Vijaya Bhatt, MBBS, Malignant Hematology
- Apar Ganti, MD, Solid Tumor Oncology
Dr. Bhatt has been with Nebraska Medicine and UNMC since 2015 and has led the leukemia disease area, as well as serving as a leader in clinical care, research and education in the malignant hematology area. He also is an associate professor in UNMC’s division of oncology and hematology.
Dr. Ganti started here in 2005 and leads the thoracic and head and neck oncology disease area for the division. He also is the associate director for clinical research for the Fred & Pamela Buffett Cancer Center and professor in UNMC’s division of oncology and hematology.
Julie Vose, MD, chief of the Nebraska Medicine Division of Hematology/Oncology, said both Dr. Bhatt and Dr. Ganti were selected as section leaders due to their strong background and commitment to clinical care, research and education in their respective areas.
In addition to these section leaders, Krishna Gundabolu, MBBS, has been appointed as the new bone marrow transplant director and medical director of level seven of C.L. Werner Cancer Hospital.
Dr. Gundabolu has had extensive training and experience in the care of leukemia and bone marrow patients through his prior education and experience at Mayo Clinic and has been on faculty in the malignant hematology/bone marrow transplant area at UNMC and Nebraska Medicine since 2014. Dr. Gundabolu also is an associate professor in UNMC’s division of oncology and hematology.
Dr. Vose said Dr. Gundabolu will continue to enhance the bone marrow transplant program by broadening the patient populations for transplant as well as CAR-T cell therapies, in addition to improving the clinical and research infrastructures for these patient populations.
“The naming of the new section leaders, Dr. Bhatt and Dr. Ganti, and having Dr. Gundabolu serve in his new leadership roles are all enhancements to our ever-growing clinical and research programs within the division of hematology/oncology,” said Dr. Vose.
Original source can be found here.
Alerts Sign-up